Industry News, Content and Resources
EU Spearheads Real-World Evidence Projects to Revolutionize Healthcare Decision-Making
The European Union is in charge of integrating real-world evidence (RWE) and advanced data analytics into healthcare decision-making to tackle the challenges of clinical evidence gathering in the era of rapid clinical innovation. Recognizing the limitations of traditional clinical trials, the EU has funded five projects [...]
Zephyr AI Secures $111M in Series A Funding to Revolutionize Healthcare with AI
Zephyr AI, a US-based healthcare technology company, has successfully raised $111 million in a Series A funding round to enhance its AI platform to improve patient care and research. Specializing in developing data federation tools and machine learning algorithms, Zephyr AI focuses on curating vast datasets [...]
FDA Outlines Regulatory Framework for AI in Medical Products
The FDA has published a comprehensive plan to regulate artificial intelligence (AI) in medical products, marking a significant step in addressing the increasing integration of AI technologies in the healthcare sector. This collaborative report, spanning various FDA centers, underscores the agency's commitment to fostering the ethical [...]
The Experimental Quest for Longevity: Rapamycin’s Rising Popularity
At 77, David Sandler from Bergen County, N.J., has ventured into an experimental approach to longevity by starting a regimen of rapamycin, a drug with a growing yet unproven reputation for extending life. Initially approved for transplant patients, rapamycin has caught the attention of the longevity [...]
AstraZeneca Boosts Rare Diseases Portfolio with Acquisition of Amolyt Pharma
AstraZeneca has announced a definitive plan on Thursday, March 14 to acquire Amolyt Pharma, a clinical-stage biotechnology company which focuses on rare endocrine diseases, for $1.05B. The deal, which includes $800M upfront and the potential for another $250M upon meeting regulatory milestones, is expected to close [...]
FDA Approves First Drug for Fatty Liver Disease by Madrigal Pharmaceuticals
The FDA has approved Madrigal Pharmaceuticals' Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), offering hope for patients with moderate to severe liver scarring. Rezdiffra, which bypassed the once-predicted liver biopsy requirement for eligibility, demonstrated efficacy in resolving MASH and improving fibrosis in the MAESTRO-NASH [...]
HEOR & Market Access Global Salary Survey (2024)
Unlock the Latest Insights in HEOR & Market Access with the 2024 Global Salary Survey Are you ready to gain an edge in your career advancement or optimize your hiring budget with the most current salary data? If so, download HealthEconomics.com’s 2024 Global Salary Survey Executive [...]
Amazon and Eli Lilly Partner for Telehealth Medication Delivery Amid Drug Shortages
Amazon has partnered with Eli Lilly to distribute select medications, including GLP-1 drugs Mounjaro and Zepbound, through LillyDirect, enhancing home delivery access for diabetes, obesity, and migraine treatments. This collaboration addresses consumer demand and drug shortages, particularly Lilly’s diabetes medication, Mounjaro. The partnership boosts Lilly’s efforts [...]
President Biden’s State of the Union: A Focus on Healthcare, Drug Pricing, and Reproductive Rights Amid Election Season
In his State of the Union address, President Joe Biden highlighted healthcare as a central priority, emphasizing the Affordable Care Act's benefits, drug pricing reforms, and the protection of reproductive rights. He celebrated the Medicare negotiation powers and cap on out-of-pocket costs introduced by the Inflation [...]
Biden Administration Proposes Increased FDA Funding for FY 2025 to Enhance Innovation and Health Services
Just days after the FDA’s fiscal year 2024 appropriations package was passed, the Biden administration is seeking a significant increase in FDA funding for fiscal year 2025, totaling $7.2 billion. This request includes appropriations and user fees, marking a $495 million overall increase. The proposed budget [...]
FDA Delays Approval of Eli Lilly’s Alzheimer’s Drug Donanemab, Citing Safety and Efficacy Concerns
Eli Lilly's Alzheimer's drug donanemab faces delays in FDA approval due to concerns over safety and efficacy, impacting the company's prospects of tapping into a potential $2.8 billion market by 2028. The FDA's decision to hold an advisory committee meeting stems from questions about the phase [...]
Beyfortus: A New Milestone in RSV Prevention for Young Children
Beyfortus, a newly developed monoclonal antibody product by AstraZeneca and Sanofi, has shown a remarkable 90% effectiveness in preventing hospitalization from Respiratory Syncytial Virus (RSV) in young children during its first season of use in the United States, surpassing its clinical trial efficacy estimates. This first [...]
GLP-1 RA Use Linked to Increased Residual Gastric Content in Fasted Patients
A cross-sectional study involving 124 fasted patients undergoing elective procedures under anesthesia revealed that users of glucagon-like peptide-1 receptor agonists (GLP-1 RA) had a significantly higher prevalence of increased residual gastric content (RGC) compared to nonusers (56% vs. 19%), despite adhering to guideline-recommended fasting durations. The [...]
Boundless Bio Eyes Nasdaq with Innovative Cancer Treatment Approach
Boundless Bio, a San Diego-based biotech startup, has announced its intention to go public on the Nasdaq under the ticker "BOLD." The company, founded five years ago and part of ARCH Venture Partners' portfolio, has raised approximately $250 million in private funding. With its innovative strategy [...]
The Stigma and Systemic Barriers Against Lifesaving Opioid Addiction Treatments in the U.S.
The opioid overdose epidemic has been devastating the U.S. for nearly three decades despite the availability of effective treatments like methadone and buprenorphine. These medications, which significantly reduce the risk of overdose and death, are underutilized due to widespread stigma and systemic barriers. A yearlong investigation [...]